

Additional file 1

Supplementary Fig 1. Mean change from baseline in HAQ-DI scores in response to abatacept administered in combination with one csDMARD from the **(a)** ATTAIN, **(b)** ASSURE, and **(c)** ARRIVE studies. Excludes patients on multiple background csDMARDs. Error bars show 95% CI. ABA, abatacept; AZA, azathioprine; CI, confidence interval; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; SSZ, sulfasalazine.

